We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

116 hedge funds and large institutions have $39.7M invested in Cardiff Oncology in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 30 increasing their positions, 37 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

908% more call options, than puts

Call options by funds: $1.19M | Put options by funds: $118K

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

5% more funds holding

Funds holding: 110 → 116 (+6)

4.49% less ownership

Funds ownership: 40.45% → 35.96% (-4.5%)

19% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 37

48% less capital invested

Capital invested by funds: $76.6M → $39.7M (-$36.8M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
116
Holders Change
+6
Holders Change %
+5.45%
% of All Funds
1.43%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
22
Increased
30
Reduced
37
Closed
13
Calls
$1.19M
Puts
$118K
Net Calls
+$1.07M
Net Calls Change
-$724K

Top Buyers

1
UBS Group
UBS Group
Switzerland
+$643K
2
Renaissance Technologies
Renaissance Technologies
New York
+$208K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$157K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$145K
5
AQR Capital Management
AQR Capital Management
Connecticut
+$136K

Top Sellers

1
William Blair & Company
William Blair & Company
Illinois
-$2.11M
2
Two Sigma Investments
Two Sigma Investments
New York
-$1.06M
3
CS
Candriam SCA
Luxembourg
-$968K
4
Goldman Sachs
Goldman Sachs
New York
-$512K
5
ACA
Acorn Capital Advisors
New York
-$411K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$6.45M -$128K -62,227 -2%
VCM
2
Vanguard Capital Management
Pennsylvania
$4.63M +$5.87M +2,855,966 New
LCM
3
Laurion Capital Management
New York
$4.29M – – –
P
4
Pfizer
New York
$3.74M – – –
ACA
5
Acorn Capital Advisors
New York
$2.85M -$411K -200,000 -10%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$2.59M +$157K +76,648 +5%
Franklin Resources
7
Franklin Resources
California
$1.95M – – –
State Street
8
State Street
Massachusetts
$1.92M -$9.65K -4,700 -0.4%
William Blair & Company
9
William Blair & Company
Illinois
$1.49M -$2.11M -1,026,440 -53%
FLPIM
10
F.L. Putnam Investment Management
Massachusetts
$964K -$413 -201 -0%
Northern Trust
11
Northern Trust
Illinois
$799K +$64.6K +31,452 +7%
VFT
12
Vanguard Fiduciary Trust
Pennsylvania
$723K +$916K +446,225 New
VPM
13
Vanguard Portfolio Management
Pennsylvania
$708K +$898K +437,214 New
UBS Group
14
UBS Group
Switzerland
$649K +$643K +313,147 +358%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$492K -$52.5K -25,567 -8%
XT
16
XTX Topco
Cayman Islands
$405K +$63.4K +30,865 +14%
Two Sigma Investments
17
Two Sigma Investments
New York
$335K -$1.06M -517,967 -71%
Charles Schwab
18
Charles Schwab
California
$267K -$49.2K -23,947 -13%
AC
19
Avestar Capital
New York
$221K – – –
Goldman Sachs
20
Goldman Sachs
New York
$220K -$512K -249,488 -65%
N
21
Nuveen
North Carolina
$211K +$103K +50,126 +62%
Citadel Advisors
22
Citadel Advisors
Florida
$203K +$15.2K +7,378 +6%
GCP
23
GSA Capital Partners
United Kingdom
$199K -$180K -87,872 -42%
AC
24
AlphaCore Capital
California
$176K -$12.3K -6,000 -5%
Renaissance Technologies
25
Renaissance Technologies
New York
$164K +$208K +101,253 New
1
2 3 4 5

CRDF Hedge Fund Activity: Q1 2026 in Review

116 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q1 2026, worth a combined $39.7M — down 48% from $76.6M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new CRDF positions and 13 closed out — a net gain of 9 holders — while 30 added to existing stakes and 37 trimmed.

The largest buyer was UBS Group, adding an estimated $643K. The largest seller was William Blair & Company, cutting an estimated $2.11M.

  • 116 institutional investors held Cardiff Oncology (CRDF) as of Q1 2026, up from 110 in Q4 2025.
  • Funds reported $39.7M of Cardiff Oncology stock for Q1 2026, down 48% quarter-over-quarter.
  • 22 funds opened new Cardiff Oncology positions in Q1 2026 and 13 closed out, a net change of +9 holders.
  • The largest Cardiff Oncology buyer in Q1 2026 was UBS Group, an estimated $643K added.
  • The largest Cardiff Oncology seller in Q1 2026 was William Blair & Company, an estimated $2.11M sold.

Based on aggregated 13F filings for Q1 2026.